Condition
Overweight
Obesity
Locations
Belgium, Bulgaria, Denmark, France, Greece, Netherlands, Poland, Spain, Sweden, United States
Start date
12/08/2026
Identifiers
Trial ID NN9932-8687,
NCT number NCT07770841,
Eudract number Not Available
NCT number NCT07770841,
Eudract number Not Available
Summary
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.
Trial Overview:
Treatment
DRUG: Semaglutide
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
Aug 12 2026 - Apr 11 2028
Participants
450
Phase
III
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.